Fig. 6: Using SLISY to identify clones that binding across multiple variants. | Nature Communications

Fig. 6: Using SLISY to identify clones that binding across multiple variants.

From: The rapid and highly parallel identification of antibodies with defined biological activities by SLISY

Fig. 6

a Selecting variant binding clones for validation. After applying the enriched pool of scFvs from biopanning with the original SARS-CoV-2 to variant proteins, the original SARS-CoV-2 SBR for each clone was plotted against a variant SBR. Clones were selected for testing based on high SBRs for both the original and variants. Twenty clones were selected from each of the original-variant pairings. b Broad spectrum neutralization by superclone scFvs Beta_10, Gamma_12, and Gamma_19. The full-length scFv phage clones were applied to wells pre-coated with variant SARS-CoV-2 spike proteins, followed by the addition of recombinant ACE2-His protein. Negative control is A3-Clone 13 scFv phage. c Ability of full-length antibodies to block variant pseudovirus infectivity. Converted full-length antibodies were incubated with pseudovirus expressing variant SARS-CoV-2 spike protein and ACE2-expressing HEK-293T cells for 48 h. Infectivity was measured by luciferase activity. Error bars represent standard deviation of means (n = 3). Source data are provided as a Source Data file.

Back to article page